Ptc Therapeutics (PTCT) EBITDA Margin (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly EBITDA Margin of 41.32% for Q2 2026, up 6087.0% year-over-year from 0.67% in Q2 2025, and up 150.51% quarter-over-quarter from 16.5% in Q1 2026.
Powered by 
Analysis
Ptc Therapeutics (PTCT) EBITDA Margin (2012 - 2026) Analysis & Trends
Ptc Therapeutics' EBITDA Margin history runs 15 years deep, the most recent figure standing at 41.32% for Q2 2026.
- In Q2 2026, EBITDA Margin rose 6087.0% year-over-year to 41.32%; the TTM figure through Jun 2026 stood at 12.45% (down 2825.0% YoY), while the FY2025 annual figure was 50.09%, up 8760.0% from the prior year.
- EBITDA Margin for Q2 2026 stood at 41.32%, up from 16.5% in the prior quarter.
- The five-year high for EBITDA Margin was 82.5% in Q1 2025, with the low at 119.67% in Q4 2022.
- The 5-year median for EBITDA Margin is 31.4% (2022), against an average of 30.66%.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin soared 12156 bps in 2023, then plunged 7807 bps in 2024.
- Ptc Therapeutics' EBITDA Margin stood at 119.67% in 2022, then jumped by 102 bps to 1.9% in 2023, then tumbled by 4119 bps to 76.18% in 2024, then jumped by 43 bps to 43.33% in 2025, then surged by 195 bps to 41.32% in 2026.
- Business Quant data shows PTCT's EBITDA Margin at 41.32% in Q2 2026, 16.5% in Q1 2026, and 43.33% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Ptc Therapeutics | 5.78 Bn | 3.55 Bn | 340.60 Mn | 41.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 41.32% |
| Mar 31, 2026 | 16.50% |
| Dec 31, 2025 | -43.33% |
| Sep 30, 2025 | 1.43% |
| Jun 30, 2025 | -19.54% |
| Mar 31, 2025 | 82.50% |
| Dec 31, 2024 | -76.18% |
| Sep 30, 2024 | -27.70% |
| Jun 30, 2024 | -21.54% |
| Mar 31, 2024 | -21.63% |
| Dec 31, 2023 | 1.90% |
| Sep 30, 2023 | -60.11% |
| Jun 30, 2023 | -98.01% |
| Mar 31, 2023 | -53.37% |
| Dec 31, 2022 | -119.67% |
| Sep 30, 2022 | -31.40% |
| Jun 30, 2022 | -55.80% |
| Mar 31, 2022 | -58.17% |
| Dec 31, 2021 | -51.28% |
| Sep 30, 2021 | -67.09% |